Neuroblastoma remains the most common extracranial solid tumor in the pediatric population. It typically arises from the sympathetic neural crest during early development. One of the most significant indicators of a poor prognosis is the amplification of the MYCN gene. However, the N-Myc protein is notoriously difficult to target directly due to its structural properties. Recent research has now identified a critical regulatory mechanism: the neuroblastoma N-Myc stabilization process driven by the NeuroD1-USP1 axis.

The study highlights how NeuroD1 acts as a master regulator in this oncogenic pathway. It transcriptionally upregulates USP1, which is a specialized deubiquitinating enzyme. Subsequently, USP1 interacts with N-Myc and removes K48-linked polyubiquitin chains. This specific action prevents the proteasomal degradation of the N-Myc protein. Therefore, the protein remains stable and active, fueling rapid tumor proliferation and progression in MYCN-amplified subtypes.

The Impact of Neuroblastoma N-Myc Stabilization on Therapy

Targeting this axis offers a fresh perspective on treating aggressive neuroblastoma. Researchers tested Pimozide, an FDA-approved antipsychotic, as a potential inhibitor in their mechanistic models. They found that Pimozide effectively suppresses USP1 expression. By reducing USP1 levels, the drug successfully promotes the degradation of N-Myc. Consequently, this intervention significantly inhibits the growth of neuroblastoma cells both in vitro and in vivo. This discovery suggests that repurposing existing drugs could bypass the traditional challenges of direct N-Myc inhibition.

Furthermore, the study used RNAseq and ChIPseq to confirm that USP1 is a direct downstream effector of NeuroD1. These findings provide a clear mechanistic link between developmental transcription factors and protein stability. These results may pave the way for future clinical trials exploring USP1 inhibitors or Pimozide in pediatric oncology. Understanding the nuances of neuroblastoma N-Myc stabilization is essential for developing more effective and targeted therapies for high-risk patients.

Frequently Asked Questions

1. What is the role of NeuroD1 in neuroblastoma progression?

NeuroD1 serves as a transcriptional regulator that promotes the expression of USP1. By increasing USP1 levels, it ensures that N-Myc remains stable and active, which directly drives the proliferation of neuroblastoma cells.

2. How does Pimozide inhibit tumor growth in these models?

Pimozide acts by suppressing the expression of USP1. When USP1 is inhibited, it can no longer stabilize N-Myc. As a result, N-Myc undergoes proteasomal degradation, leading to reduced tumor growth and increased cancer cell death.

3. Why is N-Myc considered a difficult target for drug development?

N-Myc lacks a well-defined binding pocket for small molecules, making it structurally "undruggable." Consequently, researchers focus on upstream regulatory pathways, like the NeuroD1-USP1 axis, to control N-Myc levels indirectly.

Disclaimer: This content is for informational and educational purposes only. It is not intended to provide specific medical advice or take the place of professional clinical judgment. Refer to the latest local and national guidelines for clinical practice.

References

Li G et al. NeuroD1-USP1-MYCN axis drives tumor progression in neuroblastoma. J Transl Med. 2026 Feb 11. doi: 10.1186/s12967-026-07844-5. PMID: 41673639.

Gonçalves et al. Inhibition of Cancer Stem Cells Promoted by Pimozide. ResearchGate. 2019.

Huang P et al. NeuroD1 promotes neuroblastoma cell growth by inducing the expression of ALK. Cancer Sci. 2016;107(11):1590-1598.